Metastatic Castration-resistant Prostate Cancer (mCRPC)Phase 1NCT07244393
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study testing Lutetium (177Lu) DGUL and Pembrolizumab in people with Metastatic Castration-resistant Prostate Cancer (mCRPC), run by Cellbion Co., Ltd. at 1 site in South Korea.
Trial summary
The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab. It will also assess the antitumor efficacy and pharmacokinetics of the combination therapy compared to Lutetium (177Lu) DGUL monotherapy. Read more about this study
- Who is it for?
- Ages 19 years and older, men only
- Conditions the study is for
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- What is being tested?
- Lutetium (177Lu) DGUL and Pembrolizumab
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteSouth Korea
- Study dates
- 29 Jul 2026to Apr 2029
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male patients aged 19 years or older.
- Patients with histopathologically or cytologically confirmed adenocarcinoma of the prostate, without neuroendocrine or small cell differentiation, who have metastatic disease documented by bone lesions/soft tissue lesions and are not eligible for curative treatment.
- Patients with serum testosterone levels meeting castration levels (< 50 ng/dL) at the screening visit.
- Patients must have experienced disease progression following treatment for mCRPC with a second-generation androgen receptor signaling inhibitor therapy (e.g., abiraterone or enzalutamide).
- Docetaxel treatment is allowed for localised prostate cancer and at mHSPC stage if more than 12 months have elapsed from the last dose of docetaxel, as long as no signs of failure or disease progression occurred during or immediately after such treatment.
- Patients must be receiving hormone deprivation therapy limited to the use of LHRH agonists or LHRH antagonists throughout the study. For patients who have not undergone bilateral orchiectomy, medical castration with an LHRH agonist or antagonist must have been initiated at least 4 weeks prior to baseline and must be maintained for the entire study duration.
Show all 19Show fewer
- Patients with prostate specific membrane antigen (PSMA)-positive disease, with a maximum standardized uptake value (SUVmax) of at least 20 at a site of disease and greater than 10 at other disease sites measuring ≥ 10mm in longest diameter.
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
- Patients with a life expectancy of at least 6 months.
- Patients with adequate hematologic, renal, and liver function, confirmed by the following criteria:
- Absolute neutrophil count (ANC) ≥ 1,500/μL (without granulocyte colony stimulating factor (G-CSF) administration within 2 weeks prior to baseline)
- Platelet count ≥ 100,000/μL (without transfusion within 2 weeks prior to baseline)
- Hemoglobin ≥ 9.0 g/dL (without transfusion within 4 weeks prior to baseline)
- Serum creatinine ≤ 1.8 mg/dL or Cockcroft-Gault creatinine clearance (CrCl) formula > 40 ml/min
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times the upper limit of normal (ULN), or ≤ 5 times the ULN for patients with confirmed liver metastasis
- Total bilirubin ≤ 1.5 times ULN (except in patients with Gilbert syndrome)
- Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN
- Patients who have AEs due to previous anticancer therapies must have recovered to ≤ Grade 1 or baseline. Patients with endocrine-related AEs who are adequately treated with hormone replacement or patients who have ≤ Grade 2 neuropathy are eligible.
- Patients who voluntarily agree to participate in the clinical trial and sign the informed consent form.
Who cannot join
- Known additional malignancy that is progressing or has required active treatment within the past 3 years (Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded).
- Patients who have received chemotherapy, biological therapy, or immunotherapy for prostate cancer within 4 weeks from baseline (6 weeks in the case of nitrosoureas or mitomycin).
- Any prior treatment with taxane chemotherapy for mCRPC.
- Patients with history of allogeneic stem cell transplantation (alloSCT), or solid organ transplantation.
- Patients who have received high-dose chemotherapy requiring hematopoietic stem cell treatment, within 2 years from baseline.
- Patients who have previously received PSMA-targeted treatment (e.g., radiotherapy, immunotherapy, or antibody-drug conjugate) or those treated with radiopharmaceuticals such as radium-223 within 6 months from baseline.
Show all 32Show fewer
- Patients who have previously received radiotherapy (RT) to the lung > 30 Gy within 6 months of the first dose.
- Prior exposure to any anti-programmed cell death protein 1(PD-1), anti-programmed death ligand 1/2 (PD-L1/L2), or anti- cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody, or any other agent specifically targeting T cell co-stimulation or immune checkpoint pathways.
- Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may enroll if they are radiologically stable (i.e., without evidence of progression) for at least 4 weeks, as confirmed by repeat imaging during the study screening. They must also be clinically stable and must not have required steroid treatment for at least 4 weeks before receiving the first dose of the study intervention.
- Patients with the following medical history or history of surgery/procedures:
- Deep vein thrombosis (DVT) or pulmonary embolism (PE) within 1 year from baseline.
- Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection within 6 months from baseline.
- Acute coronary syndrome (unstable angina or myocardial infarction) within 6 months from baseline.
- Major cerebrovascular disease, such as stroke, within 6 months from baseline.
- General anesthesia or major surgery requiring respiratory assistance within 4 weeks from baseline (video-assisted thoracoscopic surgery or open-and-closed (ONC) surgery allowed within 2 weeks).
- Active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid).
- History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- Patients with the following conditions:
- Class III or IV heart failure according to the New York Heart Association (NYHA) classification.
- Uncontrolled hypertension (systolic blood pressure (SBP) > 160 mm Hg or diastolic blood pressure (DBP) > 90 mm Hg).
- Clinically significant cardiovascular abnormalities as determined by the investigator (e.g., Left ventricular ejection fraction (LVEF) < 50%, clinically significant heart wall abnormalities, myocardial injury or QT interval corrected by Fridericia's formula (QTcF) > 450 msec for males or > 460 msec for females).
- Uncontrolled cardiac arrhythmia.
- Known positive human immunodeficiency virus (HIV) test or other uncontrolled active infectious diseases (e.g., Hepatitis B/C).
- Myelodysplastic syndrome (MDS).
- Clinically significant urinary obstruction or hydronephrosis that may affect renal function as determined by the investigator.
- Patients receiving nephrotoxic drugs (e.g., aminoglycosides).
- Patients with severe claustrophobia not controlled by anxiolytics.
- Patients with hypersensitivity to any components of the investigational product (IP)s.
- Patients unwilling to use appropriate contraceptive methods or abstain from intercourse during the clinical trial and for at least 4 months after discontinuation of the IPs if the patient's partner is capable of childbearing, or who do not agree to refrain from sperm donation during this period.
- Patients who have received other IPs or undergone procedures involving investigational medical devices within 4 weeks from baseline.
- Any other conditions deemed by the investigator as making the patient ineligible for clinical trial participation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Seoul National University Hospital
Seoul
About this study
Official title: A Phase 1 Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Lutetium (177Lu) DGUL in Combination With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (IGNITE Trial)
The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab. It will also assess the antitumor efficacy and pharmacokinetics of the combination therapy compared to Lutetium (177Lu) DGUL monotherapy.
Participants will:
Monotherapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals
Combination therapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals along with pembrolizumab up to 18 times at 6-week intervals
- Being tested
- Lutetium (177Lu) DGUL, Pembrolizumab
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lutetium (177Lu) DGULDrug
Lutetium (177Lu) DGUL will be administered in 4 doses at 6-week intervals (Q6W), and for patients showing good tolerance, additional 2 doses may be added, for a maximum of 6 doses.
PembrolizumabDrug
Also called KEYTRUDA®
pembrolizumab will be introduced at a dose of 400 mg every 6 weeks, beginning with the second cycle of Lutetium (177Lu) DGUL, and will continue for up to approximately 2 years (18 doses).
| Study group | Role | What they receive |
|---|---|---|
| Monotherapy Arm | Experimental | Monotherapy Arm: 10 patients will receive Lutetium (177Lu) DGUL monotherapy. Receives: Drug: Lutetium (177Lu) DGUL |
| Combination Arm | Experimental | Combination Arm: 20 patients will receive Lutetium (177Lu) DGUL in combination with pembrolizumab. Receives: Drug: Lutetium (177Lu) DGUL; Drug: Pembrolizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients with treatment-emergent adverse events (TEAEs)
Measured: From enrollment to 6-month follow-up after the end of treatment
Number of patients with drug-related TEAEs
Measured: From enrollment to 6-month follow-up after the end of treatment
Adverse events (AEs)
Measured: From enrollment to 6-month follow-up after the end of treatment
Drug-related adverse reactions based on dose limited toxicity (DLT) definitions
Measured: From enrollment to 6-month follow-up after the end of treatment
Secondary outcomes (22)
Radiographic progression-free survivla (rPFS)
Measured: From enrollment to 6-month follow-up after the end of treatment
1-year overall survivla (OS)
Measured: From enrollment to 6-month follow-up after the end of treatment
Objective response rate (ORR; confirmed complete response (CR) + partial response (PR))
Measured: From enrollment to 6-month follow-up after the end of treatment
Prostate specific antigen (PSA) response rate (>50% decrease compared to baseline PSA)
Measured: From enrollment to 6-month follow-up after the end of treatment
PSA PFS
Measured: From enrollment to 6-month follow-up after the end of treatment
Best PSA response through waterfall plot
Measured: From enrollment to 6-month follow-up after the end of treatment
Disease control rate (DCR)
Measured: From enrollment to 6-month follow-up after the end of treatment
Duration of response (DOR)
Measured: From enrollment to 6-month follow-up after the end of treatment
Tumor change rate (target lesion) through waterfall plot
Measured: From enrollment to 6-month follow-up after the end of treatment
Pain severity (numeric rating scale, NRS) and opioid analgesic use
Measured: From enrollment to 6-month follow-up after the end of treatment
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
The EORTC QLQ-C30 measures global health status, functional scales, and symptom scales. All scores range from 0 to 100.
For functional and global health scales, higher scores indicate better functioning.
For symptom scales, higher scores indicate worse symptoms.
Measured: From enrollment to 6-month follow-up after the end of treatment
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module (EORTC QLQ-PR25)
The EORTC QLQ-PR25 assesses urinary, bowel, hormonal treatment-related symptoms and sexual functioning.
Scores range from 0 to 100. For symptom scales, higher scores indicate worse symptoms. For sexual functioning, higher scores indicate better functioning.
Measured: From enrollment to 6-month follow-up after the end of treatment
Quality of Life Assessed by the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L)
The EQ-5D-5L generates an index value reflecting health status, typically ranging from less than 0 (worse than death) to 1 (full health).
Higher scores indicate better overall health. A Visual Analog Scale (0-100) may also be reported, where higher scores indicate better self-rated health.
Measured: From enrollment to 6-month follow-up after the end of treatment
Time-Activity Curve for Lutetium (177Lu) DGUL
The time-activity curve will be generated using serial imaging to quantify radioactivity kinetics of Lutetium (177Lu) DGUL in target tissues. Activity is measured in megabecquerels (MBq) over time.
Measured: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Cumulative Activity of Lutetium (177Lu) DGUL
Cumulative activity represents the total integrated activity (MBq·h) within organs or lesions over time, derived from the time-activity curve.
Measured: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Residence Time of Lutetium (177Lu) DGUL
Residence time is the time-integrated activity coefficient describing the average time (hours) that Lutetium (177Lu) DGUL remains in specific organs or lesions.
Measured: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Effective Dose of Lutetium (177Lu) DGUL
The effective dose will be calculated using organ residence times and standard dosimetry models. Effective dose is reported in millisieverts (mSv).
Measured: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Area Under the Plasma Concentration-Time Curve (AUC) of Lutetium (177Lu) DGUL
AUC represents the total systemic exposure to Lutetium (177Lu) DGUL over time. Reported in MBq·h or ng·h/mL depending on analytical method.
Measured: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Peak Plasma Concentration (Cmax) of Lutetium (177Lu) DGUL
Cmax is the highest observed plasma concentration of Lutetium (177Lu) DGUL. Reported in MBq/mL or ng/mL.
Measured: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Time to Peak Plasma Concentration (Tmax) of Lutetium (177Lu) DGUL
Tmax is the time at which Cmax occurs. Reported in hours.
Measured: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Elimination Half-Life (T1/2) of Lutetium (177Lu) DGUL
T1/2 represents the time required for the plasma concentration of Lutetium (177Lu) DGUL to decrease by 50%. Reported in hours.
Measured: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Volume of Distribution (Vd) of Lutetium (177Lu) DGUL
Vd is the apparent volume in which Lutetium (177Lu) DGUL is distributed throughout the body. Reported in liters (L).
Measured: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2025
- Study start29 Jul 2026
- Primary completionApr 2029 (estimated)
- Study completionApr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metastatic Castration-resistant Prostate Cancer (mCRPC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cellbion Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Merck Sharp & Dohme LLC
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07244393
- Sponsor's protocol ID
- Lu-PSMAPem01
- Other IDs
- KEYNOTE-G28, MK-3475-G28
- Status last verified
- Aug 2026
- First submitted
- 14 Nov 2025
- Last updated
- 7 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Lutetium (177Lu) DGUL in Combination With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (IGNITE Trial)
- ClinicalTrials.gov ID
- NCT07244393
- Acronym / sponsor ID
- Lu-PSMAPem01
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Cellbion Co., Ltd.Industry (pharma, biotech, devices)
- Collaborators
- Merck Sharp & Dohme LLC
- Study start
- 29 Jul 2026 (actual)
- Primary completion
- Apr 2029 (estimated)
- Study completion
- Apr 2029 (estimated)
- First posted
- 24 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab. It will also assess the antitumor efficacy and pharmacokinetics of the combination therapy compared to Lutetium (177Lu) DGUL monotherapy.
Participants will:
Monotherapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals
Combination therapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals along with pembrolizumab up to 18 times at 6-week intervals
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Monotherapy Arm | Experimental | Drug: Lutetium (177Lu) DGULMonotherapy Arm: 10 patients will receive Lutetium (177Lu) DGUL monotherapy. |
| Combination Arm | Experimental | Drug: Lutetium (177Lu) DGUL, Drug: PembrolizumabCombination Arm: 20 patients will receive Lutetium (177Lu) DGUL in combination with pembrolizumab. |
Who may qualify
- Ages
- 19 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (19 listed)
- Male patients aged 19 years or older.
- Patients with histopathologically or cytologically confirmed adenocarcinoma of the prostate, without neuroendocrine or small cell differentiation, who have metastatic disease documented by bone lesions/soft tissue lesions and are not eligible for curative treatment.
- Patients with serum testosterone levels meeting castration levels (< 50 ng/dL) at the screening visit.
- Patients must have experienced disease progression following treatment for mCRPC with a second-generation androgen receptor signaling inhibitor therapy (e.g., abiraterone or enzalutamide).
- Docetaxel treatment is allowed for localised prostate cancer and at mHSPC stage if more than 12 months have elapsed from the last dose of docetaxel, as long as no signs of failure or disease progression occurred during or immediately after such treatment.
Key exclusion criteria (32 listed)
- Known additional malignancy that is progressing or has required active treatment within the past 3 years (Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded).
- Patients who have received chemotherapy, biological therapy, or immunotherapy for prostate cancer within 4 weeks from baseline (6 weeks in the case of nitrosoureas or mitomycin).
- Any prior treatment with taxane chemotherapy for mCRPC.
- Patients with history of allogeneic stem cell transplantation (alloSCT), or solid organ transplantation.
- Patients who have received high-dose chemotherapy requiring hematopoietic stem cell treatment, within 2 years from baseline.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lutetium (177Lu) DGULLutetium (177Lu) DGUL will be administered in 4 doses at 6-week intervals (Q6W), and for patients showing good tolerance, additional 2 doses may be added, for a maximum of 6 doses. | Drug | Combination Arm, Monotherapy Arm |
| PembrolizumabAlso: KEYTRUDA®pembrolizumab will be introduced at a dose of 400 mg every 6 weeks, beginning with the second cycle of Lutetium (177Lu) DGUL, and will continue for up to approximately 2 years (18 doses). | Drug | Combination Arm |
Primary outcome
Number of patients with treatment-emergent adverse events (TEAEs)
Time frame: From enrollment to 6-month follow-up after the end of treatment
Number of patients with drug-related TEAEs
Time frame: From enrollment to 6-month follow-up after the end of treatment
Adverse events (AEs)
Time frame: From enrollment to 6-month follow-up after the end of treatment
Drug-related adverse reactions based on dose limited toxicity (DLT) definitions
Time frame: From enrollment to 6-month follow-up after the end of treatment
22 secondary outcomes
Radiographic progression-free survivla (rPFS)
Time frame: From enrollment to 6-month follow-up after the end of treatment
1-year overall survivla (OS)
Time frame: From enrollment to 6-month follow-up after the end of treatment
Objective response rate (ORR; confirmed complete response (CR) + partial response (PR))
Time frame: From enrollment to 6-month follow-up after the end of treatment
Prostate specific antigen (PSA) response rate (>50% decrease compared to baseline PSA)
Time frame: From enrollment to 6-month follow-up after the end of treatment
PSA PFS
Time frame: From enrollment to 6-month follow-up after the end of treatment
Best PSA response through waterfall plot
Time frame: From enrollment to 6-month follow-up after the end of treatment
Disease control rate (DCR)
Time frame: From enrollment to 6-month follow-up after the end of treatment
Duration of response (DOR)
Time frame: From enrollment to 6-month follow-up after the end of treatment
Tumor change rate (target lesion) through waterfall plot
Time frame: From enrollment to 6-month follow-up after the end of treatment
Pain severity (numeric rating scale, NRS) and opioid analgesic use
Time frame: From enrollment to 6-month follow-up after the end of treatment
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Time frame: From enrollment to 6-month follow-up after the end of treatment
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module (EORTC QLQ-PR25)
Time frame: From enrollment to 6-month follow-up after the end of treatment
Quality of Life Assessed by the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L)
Time frame: From enrollment to 6-month follow-up after the end of treatment
Time-Activity Curve for Lutetium (177Lu) DGUL
Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Cumulative Activity of Lutetium (177Lu) DGUL
Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Residence Time of Lutetium (177Lu) DGUL
Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Effective Dose of Lutetium (177Lu) DGUL
Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Area Under the Plasma Concentration-Time Curve (AUC) of Lutetium (177Lu) DGUL
Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Peak Plasma Concentration (Cmax) of Lutetium (177Lu) DGUL
Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Time to Peak Plasma Concentration (Tmax) of Lutetium (177Lu) DGUL
Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Elimination Half-Life (T1/2) of Lutetium (177Lu) DGUL
Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Volume of Distribution (Vd) of Lutetium (177Lu) DGUL
Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
Related trials for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
RecruitingObservational study
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Prostate Cancer, Prostate Adenocarcinoma
Active, not recruitingPhase 2
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
Active, not recruitingPhase 3
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
mCRPC
RecruitingPhase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Lutetium (177Lu) DGUL and Pembrolizumab in people with Metastatic Castration-resistant Prostate Cancer (mCRPC), run by Cellbion Co., Ltd. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cellbi on (8227433311, boyoung@cellbion.co.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients with treatment-emergent adverse events (TEAEs) (time frame: From enrollment to 6-month follow-up after the end of treatment). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.